Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06482853 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 31 words
  2. Eligibility criteria expanded, about 11 wordsv6
  3. Start date changed from estimate of Mar 2025 to Jan 23, 2025v5
  4. Start date: Dec 2024 to Mar 2025v4
  5. Site contact updatedv3
  6. Start date: Aug 2024 to Dec 2024
    • Site contact updated
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Obesity is a global health concern that is associated with high blood pressure and an increased risk for developing cardiovascular disease. The purpose of this study is to find out if the investigational drug angiotensin-(1-7) can improve cardiovascular health in people with obesity and high blood pressure.
Trial Details
NCT Number NCT06482853
Lead Sponsor Milton S. Hershey Medical Center
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions
(from sponsor)		 Obesity, Hypertension
Related terms Hypertension, Obesity
Enrollment 52 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov